Latest Paliperidone Stories
HAMILTON, N.J., Sept. 14 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of CNS disorders, announced today that the U.S.
WALTHAM, Mass., Aug.
TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGAÂ® SUSTENNAÂ® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDALÂ® CONSTAÂ® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans.
WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013.
A study published today in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications.
The use of atypical antipsychotics to treat elderly patients with dementia appears to have decreased following a 2005 Food and Drug Administration (FDA) advisory regarding the risks of these medications in this population.
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGAÂ® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDALÂ® CONSTAÂ®, according to new data from a comparative study of both treatments in patients with schizophrenia.
WALTHAM, Mass., Dec.
TITUSVILLE, N.J., Aug. 3 /PRNewswire/ -- The U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults on Friday, July 31, 2009.
Invega Sustenna, a longer-acting anti-psychotic medication for schizophrenia, has been approved by the U.S.